TLR4 pathway inhibition reversed tumor-mediated suppression of both natural killer cell activity as well as T-cell proliferation in vitro and in vivo, resulting in increased tumor latency and survival of tumor-bearing mice (44). The gene discussed is TLR4; the disease is neoplasm.